Citizens JMP raised the firm’s price target on OptimizeRx (OPRX) to $20 from $14 and keeps an Outperform rating on the shares following the Q2 beat. Management expressed comfort with consensus 2026 revenue and EBITDA estimates, the analyst tells investors in a research note. The firm lifted estimates post the quarter.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPRX:
- OptimizeRx Reports Strong Q2 2025 Financial Growth
- OptimizeRx price target raised to $27 from $22 at Roth Capital
- OptimizeRx: Strong Q2 Performance and Upgraded Guidance Justify Buy Rating
- OptimizeRx reports Q2 EPS 24c, consensus 2c
- OptimizeRx raises 2025 sales outlook to $104M-$108M, consensus $103.35M